Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
Galimberti
S
S
Canestraro
M
M
Khan
R
R
Buda
G
G
Orciuolo
E
E
Guerrini
F
F
Fazzi
R
R
Maffei
R
R
Marasca
R
R
Petrini
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D045744:Cell Line, Tumor / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D016162:Genes, Wilms Tumor / Q000187:drug effects*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D007947:Leukemia, Megakaryoblastic, Acute / Q000473:pathology; D015477:Leukemia, Myelomonocytic, Chronic / Q000473:pathology; D008533:Megakaryocytes / Q000187:drug effects / Q000378:metabolism; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D011719:Pyrazines / Q000494:pharmacology*; D000077337:Vorinostat; D025721:WT1 Proteins / Q000096:biosynthesis*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D009363:Neoplasm Proteins; D011719:Pyrazines; D025721:WT1 Proteins; D000077337:Vorinostat; D000069286:Bortezomib